Pediatric immune dysregulation nursing requires explaining three management decisions that each appear to contradict the stated diagnosis. An eight-month-old whose disease mechanism is that his immune system attacks his own tissues — whose parents have been told to give him a medication that reduces immune system activity — and who ask why weakening his immune system is the answer when the problem is that his immune system is already doing the wrong thing. An eight-year-old with enormous lymph nodes and a spleen his parents can almost feel through his abdomen, who has had two biopsies confirming no cancer, and whose parents cannot understand why the monitoring continues when the biopsies gave a definitive answer. And an eleven-year-old who was diagnosed two years ago with antibody deficiency — a weak immune system — who now has autoimmune enteropathy destroying her intestinal lining and is being offered a medication her parents have researched and found is used for rheumatoid arthritis and other conditions where the immune system is too strong.
Each family is in the same structural position: the proposed management is correct, the mechanism is real, and the apparent contradiction resolves with a mechanistic explanation that translated handouts cannot supply. The IPEX parents’ model of the immune system is accurate — the immune system is a defense system and reducing it increases infection risk. What their model is missing is the two-arm structure of immune function: effector arm that attacks targets, regulatory arm that prevents attack on self. The ALPS parents’ reading of the biopsies is accurate — the biopsies confirmed benign lymphocytes, not cancer. What their model is missing is that FAS pathway failure creates a prospective cancer risk that is entirely separate from whether current lymphocytes are benign. The LRBA parents’ diagnosis of antibody deficiency is accurate — their daughter’s B cells cannot make sufficient IgG or IgA. What their model is missing is that the same LRBA gene simultaneously regulates T cell CTLA-4 recycling, producing dysregulated T cell activation in a completely different cell type.
The three conversations in this post take place in Houston, San Antonio, and Dallas — in the outpatient pediatric immune dysregulation and clinical immunology clinics of Texas children’s hospitals serving Spanish-speaking working families. The nurse who can explain the two-arm model of immune regulation to Emilio’s parents, the dual-consequence model of FAS apoptosis failure to Andrés’s parents, and the dual-mechanism model of LRBA deficiency to Valentina’s parents is the nurse who changes the decisions these families make between clinic visits.
Scenario 1: Emilio Herrera-Cruz — Houston, Texas
Pediatric immune dysregulation nurse Daniela Fuentes-Torres and the parents who cannot understand why their baby needs immunosuppression when the immune system is already attacking his body
Emilio is eight months old. He lives in Houston with Sandra Herrera-García, twenty-nine, a home healthcare aide, and Marcos Cruz-Torres, thirty-two, a plumber. Emilio’s newborn course was uncomplicated. At six weeks of age he developed profuse watery diarrhea averaging twelve stools per day. At three months his pediatrician noted severe eczematous dermatitis involving approximately 60% of his body surface area and referred him to pediatric dermatology. At five months his pediatrician noted poor weight gain and obtained a random blood glucose: 498 mg/dL. He was admitted to the pediatric hospital for diabetic ketoacidosis. The inpatient team noted the combination of neonatal-onset diabetes, secretory diarrhea, and severe eczema in a male infant and sent a FOXP3 gene panel. The result returned: FOXP3 hemizygous c.1150G>A p.Asp384Asn, a pathogenic variant in the forkhead domain. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome — IPEX syndrome — was diagnosed. Emilio was started on insulin for T1DM management, hydrolyzed formula for enteropathy, and topical corticosteroids for eczema. Sirolimus was recommended to suppress the autoimmune attack. Sandra and Marcos declined the sirolimus.
Today is the two-week post-discharge clinic visit. Emilio is on insulin, formula, and skin care. His blood glucose is marginally controlled at 210–380 mg/dL range. His diarrhea has not improved — averaging ten stools per day. His eczema has worsened on the topical regimen alone. He is not gaining weight. Nurse Daniela Fuentes-Torres sits with Sandra and Marcos.
Sandra: “Enfermera Fuentes-Torres, entendemos que el sistema inmune de Emilio lo está atacando. Nos explicaron que los linfocitos atacan el páncreas, el intestino y la piel. Y ahora nos dicen que la solución es un medicamento que debilita el sistema inmune. ¿Cómo es posible que debilitar el sistema que ya está atacando a Emilio sea la respuesta? Si lo debilitamos más, ¿no va a quedar sin defensa contra las infecciones?”
(Nurse Fuentes-Torres, we understand that Emilio’s immune system is attacking him. They explained that lymphocytes attack the pancreas, the intestine, and the skin. And now they tell us the solution is a medication that weakens the immune system. How is it possible that weakening the system that is already attacking Emilio is the answer? If we weaken it further, won’t he be left defenseless against infections?)
Marcos: “Es lo que no podemos entender. Si le damos algo que hace más débil el sistema, ¿no va a ser peor?”
(That is what we cannot understand. If we give him something that makes the system weaker, won’t it be worse?)
Nurse Daniela Fuentes-Torres recognizes that both parents are reasoning correctly from their model of how the immune system works. She needs to explain the two-arm structure of immune function before she can explain what sirolimus does and why it is the treatment.
“Sandra, Marcos — tienen toda la razón en preguntar esto. Y la pregunta tiene sentido porque el sistema inmune suena como una sola cosa, cuando en realidad tiene dos partes que hacen cosas opuestas al mismo tiempo. Necesito explicarles esas dos partes para que lo que le pasa a Emilio tenga sentido. La primera parte son los linfocitos efectores — los que atacan infecciones, bacterias, virus. Eso es lo que normalmente pensamos que hace el sistema inmune. La segunda parte son los linfocitos reguladores — los que frenan a los efectores para que no ataquen el propio cuerpo. Estos son los linfocitos T reguladores, o Tregs, y dependen de una proteína que se llama FOXP3 para existir y funcionar. La mutación de Emilio — en el gen FOXP3 — elimina los linfocitos reguladores. No reduce los efectores. Emilio tiene linfocitos efectores completamente funcionales. Lo que no tiene es el freno.”
(Sandra, Marcos — you are completely right to ask this. And the question makes sense because the immune system sounds like one thing, when in reality it has two parts that do opposite things at the same time. I need to explain those two parts for what happens to Emilio to make sense. The first part is the effector lymphocytes — the ones that attack infections, bacteria, viruses. That is what we normally think the immune system does. The second part is the regulatory lymphocytes — the ones that brake the effectors so they do not attack the body itself. These are regulatory T lymphocytes, or Tregs, and they depend on a protein called FOXP3 to exist and function. Emilio’s mutation — in the FOXP3 gene — eliminates the regulatory lymphocytes. It does not reduce the effectors. Emilio has completely functional effector lymphocytes. What he does not have is the brake.)
Sandra: “¿Y sin el freno, los efectores hacen lo que quieren?”
(And without the brake, the effectors do what they want?)
“Exactamente. Los linfocitos efectores son como un auto con motor. Los reguladores son el freno. En un niño sano, cuando termina una infección, los reguladores frenan a los efectores y el ataque para. En Emilio, no hay freno — los efectores siguen activos después de que terminan las infecciones y empiezan a atacar el propio cuerpo de Emilio. Atacan las células beta del páncreas que hacen insulina — por eso tiene diabetes. Atacan las células del intestino — por eso tiene la diarrea persistente. Atacan la piel — por eso tiene el eccema severo. Los tres problemas de Emilio son la misma causa: linfocitos efectores sin freno. La solución no es debilitar el sistema inmune en general. Es reducir la activación de los linfocitos efectores específicamente — los que están causando el daño.”
(Exactly. Effector lymphocytes are like a car with an engine. The regulatory ones are the brake. In a healthy child, when an infection ends, the regulatory ones brake the effectors and the attack stops. In Emilio, there is no brake — the effectors keep active after infections end and begin attacking Emilio’s own body. They attack the pancreatic beta cells that make insulin — that is why he has diabetes. They attack the intestinal cells — that is why he has the persistent diarrhea. They attack the skin — that is why he has the severe eczema. Emilio’s three problems have the same cause: effector lymphocytes without a brake. The solution is not to weaken the immune system in general. It is to reduce the activation of effector lymphocytes specifically — the ones causing the damage.)
Marcos: “¿Y si reducimos los efectores, no va a poder pelear las infecciones?”
(And if we reduce the effectors, won’t he be able to fight infections?)
“El sirolimus tiene una ventaja importante aquí: funciona diferente en los linfocitos efectores y en los reguladores. Los efectores dependen más de la señal mTOR para proliferar con fuerza. Los reguladores dependen menos de esa señal. El sirolimus bloquea mTOR — eso reduce los efectores más que los reguladores. En Emilio, el objetivo es reducir la proliferación de los efectores que están atacando el páncreas y el intestino. ¿Eso conlleva algún riesgo de infección? Sí, hay algo más de riesgo, y por eso vigilamos muy de cerca y tratamos las infecciones rápidamente. Pero lo que pasa sin el sirolimus es que los efectores siguen destruyendo las células beta restantes del páncreas de Emilio, siguen dañando el intestino hasta que absorbe cada vez menos, y siguen atacando la piel. No es protección — es seguir perdiendo.”
(Sirolimus has an important advantage here: it works differently in effector and regulatory lymphocytes. Effectors depend more on the mTOR signal to proliferate strongly. Regulators depend less on that signal. Sirolimus blocks mTOR — that reduces effectors more than regulators. In Emilio, the goal is to reduce the proliferation of the effectors that are attacking the pancreas and intestine. Does that carry some infection risk? Yes, there is somewhat more risk, and that is why we watch very closely and treat infections quickly. But what happens without sirolimus is that the effectors continue destroying Emilio’s remaining pancreatic beta cells, continue damaging the intestine until it absorbs less and less, and continue attacking the skin. That is not protection — it is continued loss.)
Sandra took Emilio’s hand. “¿Y hay algo que lo cure?”
(And is there something that cures him?)
“El único tratamiento curativo para el IPEX es el trasplante de células madre hematopoyéticas. Las células madre de Emilio tienen la mutación en FOXP3 — todos los linfocitos que producen tienen el mismo defecto. Si reemplazamos las células madre con células de un donante sano, los nuevos linfocitos T que se producen a partir de esas células sí tienen el FOXP3 normal, y pueden desarrollar linfocitos reguladores que hagan el trabajo de frenar a los efectores. El sirolimus es para controlar el daño mientras se busca un donante compatible y se prepara el trasplante. Lo que están protegiendo con el sirolimus ahora mismo son las células beta que le quedan a Emilio y la mucosa intestinal que todavía funciona.”
(The only curative treatment for IPEX is hematopoietic stem cell transplantation. Emilio’s stem cells have the FOXP3 mutation — all the lymphocytes they produce have the same defect. If we replace the stem cells with cells from a healthy donor, the new T lymphocytes produced from those cells do have normal FOXP3, and they can develop regulatory lymphocytes that do the work of braking the effectors. Sirolimus is to control the damage while a compatible donor is sought and the transplant is prepared. What sirolimus is protecting right now are Emilio’s remaining beta cells and the intestinal mucosa that still functions.)
Sandra and Marcos agreed to start sirolimus that day. At the four-week follow-up Emilio’s diarrhea had decreased from ten stools per day to four. His eczema had improved from 60% to 35% BSA involvement. His blood glucose range had narrowed to 140–220 mg/dL on the same insulin regimen. HLA typing was sent on Emilio and his family members. At six months an HLA-matched sibling donor was identified; HSCT was performed at eight months of age. At eighteen months post-transplant Emilio’s FOXP3 chimerism was 94% donor; his eczema had resolved; his diarrhea was gone; his insulin requirements had plateaued, reflecting the beta cell mass that survived the autoimmune attack before the transplant. Sandra at the eighteen-month visit: “Cuando nos explicaron de los linfocitos reguladores — el freno — ya entendí por qué el sirolimus era para parar el ataque, no para quitar la defensa. Esa explicación fue lo que nos convirtió.” (“When they explained the regulatory lymphocytes — the brake — I understood why sirolimus was to stop the attack, not to remove the defense. That explanation was what convinced us.”)
Scenario 2: Andrés Vásquez-Torres — San Antonio, Texas
Pediatric immune dysregulation nurse Carmen Santos-Morales and the parents who cannot understand why monitoring continues when biopsies confirmed no cancer
Andrés is eight years old. He lives in San Antonio with Marisol Vásquez-Cruz, thirty-eight, an elementary school teacher, and Roberto Torres-Espinoza, forty-one, a warehouse supervisor. At age five, Marisol noticed that Andrés’s neck lymph nodes had been enlarged for several months. His pediatrician referred him to pediatric surgery for excisional biopsy. Pathology: “Reactive lymphoid hyperplasia; no evidence of malignancy.” At age six, the adenopathy had increased to include axillary and inguinal nodes, and he developed palpable splenomegaly. A second excisional biopsy was performed. Pathology: “Reactive lymphoid hyperplasia; polyclonal B cell expansion; no evidence of malignancy.” Pediatric oncology evaluated Andrés and ordered an immune evaluation. Flow cytometry showed double-negative T cells (TCRαβ+CD3+CD4−CD8−) at 4.2% of peripheral lymphocytes (normal <1%). Vitamin B12: 2,840 pg/mL (normal <900). Soluble CD25: 3,920 U/mL (elevated). FAS gene sequencing: heterozygous pathogenic variant c.748C>T p.Arg250Trp in the death domain. Coombs-positive hemolytic anemia. Diagnosis: ALPS-FAS. Andrés was referred to the pediatric immune dysregulation clinic. He is followed quarterly with blood tests and annually with cross-sectional imaging. He is on mycophenolate mofetil to reduce lymphoproliferation and monthly folate supplementation for hemolytic anemia support.
Marisol and Roberto are at today’s quarterly visit. Andrés is asymptomatic — playing soccer, performing at grade level, no B symptoms.
Roberto: “Enfermera Santos-Morales, han pasado tres años desde el primer diagnóstico. Dos biopsias. Las dos dicen lo mismo: linfocitos benignos, sin cáncer. Los análisis cada tres meses, imágenes una vez al año. Andrés está perfectamente bien. No entendemos por qué seguimos con tanto seguimiento cuando la biopsia ya dijo que no es cáncer. ¿Para qué sirven los análisis si la biopsia ya respondió la pregunta?”
(Nurse Santos-Morales, three years have passed since the first diagnosis. Two biopsies. Both say the same: benign lymphocytes, no cancer. Blood tests every three months, imaging once a year. Andrés is perfectly well. We do not understand why we continue with so much follow-up when the biopsy already said it is not cancer. What are the blood tests for if the biopsy already answered the question?)
Marisol: “Y si en tres años no ha pasado nada, ¿no es eso una señal de que el riesgo no es tan alto?”
(And if in three years nothing has happened, isn’t that a signal that the risk is not so high?)
Nurse Carmen Santos-Morales recognizes that the family is using the biopsies as their primary reference point for cancer risk, and that their reasoning — two definitive pathology reports saying no cancer — is locally correct and globally incomplete. She needs to explain the two separate consequences of FAS apoptosis failure before she can explain why the biopsies answer one question and the surveillance addresses a different one.
“Quiero explicarles cómo funciona la mutación de Andrés, porque lo que hacen las biopsias y lo que hacen los análisis trimestrales responden a dos preguntas completamente distintas. Empiezo por la mutación. La proteína FAS — la que tiene la mutación de Andrés — es la señal de muerte para los linfocitos. Después de que el sistema inmune combate una infección, la mayoría de los linfocitos activados reciben una señal de FAS que les dice que su trabajo terminó y que deben morir para que el cuerpo no quede con demasiados linfocitos acumulados. En Andrés, esa señal de muerte no funciona bien — la mutación está en el dominio de la muerte de la proteína FAS, y aunque tiene una copia normal del gen, la mutación dominante interfiere con la señal incluso cuando la copia normal está presente. Los linfocitos que deberían morir después de cada infección no mueren. Se acumulan.”
(I want to explain how Andrés’s mutation works, because what the biopsies do and what the quarterly blood tests do answer two completely different questions. I start with the mutation. The FAS protein — the one Andrés’s mutation affects — is the death signal for lymphocytes. After the immune system fights an infection, most of the activated lymphocytes receive a FAS signal telling them their work is done and they should die so the body does not end up with too many accumulated lymphocytes. In Andrés, that death signal does not work well — the mutation is in the death domain of the FAS protein, and even though he has one normal copy of the gene, the dominant mutation interferes with the signal even when the normal copy is present. The lymphocytes that should die after each infection do not die. They accumulate.)
Roberto: “¿Y esos son los que están en los ganglios y el bazo?”
(And those are the ones that are in the lymph nodes and the spleen?)
“Exactamente. Los ganglios grandes de Andrés y el bazo agrandado son esos linfocitos acumulados en los últimos años. Hay un tipo específico de linfocito que se acumula en el ALPS — se llama linfocito T doble negativo, el que tienen ál 4,2% de los de Andrés cuando lo normal es menos del 1%. Son linfocitos que no murieron y siguen ahí. Ahora bien — ¿son malignos esos linfocitos? Las biopsias responden esa pregunta perfectamente: no. Son linfocitos normales, reactivos, benignos. Las biopsias están en lo correcto. La acumulación de Andrés ahora mismo es benigna. Eso es lo que confirman las biopsias — el estado actual de los linfocitos acumulados.”
(Exactly. Andrés’s large lymph nodes and enlarged spleen are those accumulated lymphocytes from the past years. There is a specific type of lymphocyte that accumulates in ALPS — it is called double-negative T lymphocyte, the kind that Andrés has at 4.2% when the normal is less than 1%. They are lymphocytes that did not die and are still there. Now — are those lymphocytes malignant? The biopsies answer that question perfectly: no. They are normal, reactive, benign lymphocytes. The biopsies are correct. Andrés’s accumulation right now is benign. That is what the biopsies confirm — the current state of the accumulated lymphocytes.)
Marisol: “Entonces las biopsias dicen que no hay cáncer. ¿Por qué seguimos vigilando?”
(So the biopsies say there is no cancer. Why do we continue monitoring?)
“Porque hay una segunda consecuencia de la mutación de Andrés que es completamente separada de si los linfocitos acumulados ahora mismo son benignos o no. La vía FAS — la señal de muerte — no solo elimina linfocitos después de infecciones. También elimina linfocitos que tienen daño en el ADN — los que, si no se eliminan, pueden convertirse en cáncer. Eso es uno de los mecanismos que el cuerpo usa para evitar que el cáncer se desarrolle: eliminar las células con mutaciones peligrosas antes de que proliferen. En Andrés, esa eliminación tampoco funciona bien — la misma mutación que no deja morir a los linfocitos normales también dificulta eliminar los que tienen daño en el ADN. Los pacientes con ALPS tienen diez a quince veces más riesgo de linfoma que la población general, principalmente linfoma de Hodgkin y linfoma difuso de células B grandes. Eso no significa que Andrés va a tener linfoma — significa que el riesgo es mayor y que hay que vigilarlo.”
(Because there is a second consequence of Andrés’s mutation that is completely separate from whether the currently accumulated lymphocytes are benign or not. The FAS pathway — the death signal — does not only eliminate lymphocytes after infections. It also eliminates lymphocytes that have DNA damage — the ones that, if not eliminated, could become cancer. That is one of the mechanisms the body uses to prevent cancer from developing: eliminating cells with dangerous mutations before they proliferate. In Andrés, that elimination also does not work well — the same mutation that does not let normal lymphocytes die also makes it harder to eliminate those with DNA damage. ALPS patients have ten to fifteen times more lymphoma risk than the general population, mainly Hodgkin lymphoma and diffuse large B cell lymphoma. That does not mean Andrés will have lymphoma — it means the risk is higher and it needs to be monitored.)
Roberto: “¿Y la biopsia no detectaría ese cambio?”
(And wouldn’t the biopsy detect that change?)
“El problema es que el linfoma en el ALPS se desarrolla en un contexto de adenopatía y esplenomegalia que ya existían. Andrés tiene ganglios grandes y bazo grande desde hace años — eso es la base. Si apareciera un linfoma, no podríamos detectarlo por los síntomas de Andrés porque ya tiene esos síntomas. Los análisis trimestrales — la vitamina B12, el sCD25, el porcentaje de linfocitos doble negativos, la LDH, la ferritina — miden si hay cambios en los marcadores que indican activación inmune fuera de lo esperado para el ALPS estático. Una LDH que sube de manera sostenida, una nueva población clonal en la citometría de flujo, un cambio en el patrón de los marcadores — esos son los signos de que algo está cambiando. Las imágenes anuales buscan nuevos focos de engrosamiento ganglionar o cambios de arquitectura que sugieran transformación maligna. Las biopsias confirmaron lo que ya sabíamos — la acumulación actual es benigna. Los análisis trimestrales buscan otra cosa: si esa acumulación benigna empieza a transformarse. Son dos preguntas distintas que necesitan herramientas distintas.”
(The problem is that lymphoma in ALPS develops in a context of adenopathy and splenomegaly that already existed. Andrés has large lymph nodes and an enlarged spleen for years — that is the baseline. If a lymphoma appeared, we could not detect it by Andrés’s symptoms because he already has those symptoms. The quarterly blood tests — vitamin B12, sCD25, the percentage of double-negative lymphocytes, LDH, ferritin — measure whether there are changes in the markers that indicate immune activation beyond what is expected for static ALPS. A LDH that rises steadily, a new clonal population on flow cytometry, a change in the pattern of markers — those are the signs that something is changing. The annual imaging looks for new foci of lymph node thickening or architectural changes suggesting malignant transformation. The biopsies confirmed what we already knew — the current accumulation is benign. The quarterly tests look for something else: whether that benign accumulation is beginning to transform. They are two different questions that need different tools.)
Marisol was quiet for a moment. “¿Los análisis de hace tres años hasta hoy han mostrado algo diferente?”
(Have the tests from three years ago until today shown anything different?)
“No — los marcadores de Andrés han sido consistentes en el rango esperado del ALPS. La vitamina B12 se ha mantenido entre 2,400 y 2,900, el sCD25 entre 3,200 y 4,100, la LDH normal. Eso es bueno — significa que en este momento no hay señales de transformación. Pero esa estabilidad de tres años es exactamente la información que obtenemos del seguimiento. Sin esos análisis, no tendríamos esa tranquilidad. Y si algo cambiara, lo detectaríamos en los análisis antes de que Andrés tuviera síntomas nuevos.”
(No — Andrés’s markers have been consistent in the expected ALPS range. Vitamin B12 has stayed between 2,400 and 2,900, sCD25 between 3,200 and 4,100, LDH normal. That is good — it means at this moment there are no signs of transformation. But that three-year stability is exactly the information we get from follow-up. Without those tests, we would not have that reassurance. And if something changed, we would detect it in the tests before Andrés had new symptoms.)
Roberto nodded. “Entonces los análisis no buscan el cáncer que existe ahora. Buscan el cambio que puede llegar.”
(So the tests are not looking for cancer that exists now. They are looking for the change that might come.)
“Exactamente. Son dos preguntas distintas. Las biopsias respondieron la primera. El seguimiento trimestral responde la segunda, continuamente.”
(Exactly. Two different questions. The biopsies answered the first. The quarterly follow-up answers the second, continuously.)
Andrés continued quarterly monitoring. At age eleven his markers remain stable. At age nine he participated in an ALPS natural history study; his DNT cells had decreased from 4.2% to 3.1% on mycophenolate mofetil, his spleen had reduced from 18 cm to 14 cm, and his hemolytic anemia had resolved. Marisol at the most recent visit: “La primera vez que nos explicaron que los análisis y las biopsias responden preguntas distintas, por fin entendí por qué las dos son necesarias. La biopsia dice cómo están los ganglios hoy. Los análisis dicen si algo está cambiando en dirección a algo peor. Son distintos.” (“The first time they explained that the blood tests and the biopsies answer different questions, I finally understood why both are necessary. The biopsy says how the lymph nodes are today. The blood tests say whether something is changing toward something worse. They are different.”)
Scenario 3: Valentina Morales-García — Dallas, Texas
Pediatric immune dysregulation nurse Isabel Torres-Cisneros and the parents who cannot understand why an autoimmune medication is being added when the diagnosis was a weak immune system
Valentina is eleven years old. She lives in Dallas with Carmen Morales-Espinoza, thirty-nine, a school cafeteria worker, and Ernesto García-Torres, forty-three, an electrician. At age nine Valentina was evaluated for recurrent sinopulmonary infections: three bacterial pneumonias in eighteen months, four sinusitis episodes requiring oral antibiotics, and one hospitalization for Haemophilus influenzae bacteremia. Immune evaluation showed IgG 284 mg/dL (normal ≥700), undetectable IgA, IgM 18 mg/dL, absent specific antibody responses to vaccine antigens (measles, tetanus, pneumococcal polysaccharide). Diagnosis: common variable immunodeficiency phenotype, subsequently refined by gene panel to LRBA deficiency (compound heterozygous LRBA c.4024C>T p.Arg1342Cys / c.6340G>T p.Glu2114Ter). She was started on IVIG 600 mg/kg every four weeks. Over two years on IVIG she has not had a single pneumonia. Her IgG trough on IVIG is 820 mg/dL. Her parents have been very adherent to the monthly infusion schedule and understand it as “replacing the antibodies her immune system cannot make.”
Four months ago Valentina developed progressive chronic watery diarrhea averaging eight to ten stools per day. She has lost 4.2 kg. Duodenal biopsy shows villous atrophy, increased intraepithelial lymphocytes, and crypt hyperplasia. IgG anti-enterocyte antibodies are positive at 1:640. CRP 28 mg/L. The gastroenterology and immune dysregulation teams have recommended abatacept for autoimmune enteropathy. Carmen and Ernesto have researched abatacept and found it is used for rheumatoid arthritis and juvenile idiopathic arthritis. They are confused and worried.
Carmen: “Enfermera Torres-Cisneros, cuando nos diagnosticaron a Valentina a los nueve años, nos dijeron que tiene el sistema inmune débil — que no produce suficientes anticuerpos y que el IVIG reemplaza lo que no puede hacer. Eso lo entendimos bien y llevamos dos años sin pulmonías. Ahora nos dicen que tiene una enfermedad autoinmune en el intestino y que necesita abatacept. Buscamos el abatacept y es para artritis reumatoide — una enfermedad donde el sistema inmune es demasiado fuerte. Pero Valentina tiene el sistema débil. ¿Cómo puede necesitar medicamentos para las dos cosas al mismo tiempo?”
(Nurse Torres-Cisneros, when Valentina was diagnosed at nine, they told us she has a weak immune system — that she does not produce enough antibodies and IVIG replaces what it cannot do. We understood that well and have had two years without pneumonias. Now they tell us she has an autoimmune disease in the intestine and needs abatacept. We researched abatacept and it is for rheumatoid arthritis — a disease where the immune system is too strong. But Valentina has a weak system. How can she need medications for both things at the same time?)
Ernesto: “Para nosotros no tiene sentido. Si el sistema es débil, reforzarlo. Si es fuerte, frenarlo. No puede ser las dos cosas.”
(To us it does not make sense. If the system is weak, strengthen it. If it is strong, brake it. It cannot be both things.)
Nurse Isabel Torres-Cisneros recognizes that the family has built an accurate binary model of immune function — weak vs. strong — and that LRBA deficiency requires explaining how the same gene can simultaneously produce both consequences in different cell types. She needs to establish what LRBA does before explaining what IVIG and abatacept each address.
“Carmen, Ernesto — la contradicción que ven es real dentro del modelo que nos dieron al principio, y entiendo por qué no tiene sentido. Necesito explicarles lo que hace la proteína LRBA para que lo que le pasa a Valentina tenga sentido. La LRBA es una proteína que está dentro de las células y que ayuda a reciclar otras proteínas — es como un sistema de reciclaje de mensajeros dentro de la célula. Hay una proteína que depende de ese reciclaje para funcionar bien que se llama CTLA-4. El CTLA-4 está en la superficie de los linfocitos T activados y su función es parar la activación de los linfocitos T cuando ya no es necesaria. Es el freno de los linfocitos T. El CTLA-4 entra y sale de la superficie de la célula constantemente — entra, se recicla, y vuelve a la superficie. Sin la proteína LRBA, el CTLA-4 no puede reciclarse — en lugar de volver a la superficie, se destruye dentro de la célula. El resultado es que la superficie de los linfocitos T de Valentina tiene muy poco CTLA-4 — muy poco freno.”
(Carmen, Ernesto — the contradiction you see is real within the model we were given at the beginning, and I understand why it does not make sense. I need to explain what the LRBA protein does for what happens to Valentina to make sense. LRBA is a protein inside cells that helps recycle other proteins — it is like a messenger recycling system inside the cell. There is a protein that depends on that recycling to function well called CTLA-4. CTLA-4 is on the surface of activated T lymphocytes and its function is to stop T lymphocyte activation when it is no longer necessary. It is the brake for T lymphocytes. CTLA-4 constantly enters and exits the cell surface — it enters, it is recycled, and it returns to the surface. Without the LRBA protein, CTLA-4 cannot be recycled — instead of returning to the surface, it is destroyed inside the cell. The result is that Valentina’s T lymphocyte surface has very little CTLA-4 — very little brake.)
Carmen: “¿Y eso qué produce?”
(And what does that produce?)
“Los linfocitos T se activan más de lo necesario porque no tienen suficiente freno. En el intestino de Valentina, esos linfocitos T activados atacan el epitelio intestinal — las células que forman las vellosidades y absorben los nutrientes. Por eso la biopsia muestra atrofia vellositaria y linfocitos aumentados en el epitelio: son linfocitos T que están atacando el revestimiento intestinal. Eso es la enteropatía autoinmune. Eso es un problema del lado T del sistema inmune. Ahora el otro problema — el que Valentina tenía desde los nueve años: las células B de Valentina, los linfocitos que producen anticuerpos, también dependen de la LRBA para sobrevivir y madurar. Sin LRBA, las células B no pueden completar la maduración necesaria para producir IgG e IgA suficiente. Eso produce la deficiencia de anticuerpos. Ese es un problema del lado B del sistema inmune. La misma mutación en LRBA produce dos consecuencias: en las células B, deficiencia de anticuerpos; en los linfocitos T, activación desregulada por falta de CTLA-4.”
(T lymphocytes activate more than necessary because they do not have enough brake. In Valentina’s intestine, those activated T lymphocytes attack the intestinal epithelium — the cells that form the villi and absorb nutrients. That is why the biopsy shows villous atrophy and increased lymphocytes in the epithelium: they are T lymphocytes attacking the intestinal lining. That is the autoimmune enteropathy. That is a problem on the T side of the immune system. Now the other problem — the one Valentina has had since age nine: Valentina’s B cells, the lymphocytes that produce antibodies, also depend on LRBA to survive and mature. Without LRBA, B cells cannot complete the maturation needed to produce sufficient IgG and IgA. That produces the antibody deficiency. That is a problem on the B side of the immune system. The same LRBA mutation produces two consequences: in B cells, antibody deficiency; in T lymphocytes, dysregulated activation from lack of CTLA-4.)
Ernesto: “¿Y los dos tratamientos son para los dos problemas distintos?”
(And the two treatments are for the two different problems?)
“Exactamente. El IVIG reemplaza los anticuerpos que las células B de Valentina no pueden hacer — eso soluciona el problema del lado B. El abatacept es exactamente la proteína CTLA-4, hecha como medicamento. Cuando se administra el abatacept, el CTLA-4 del medicamento se une a las mismas moléculas a las que se uniría el CTLA-4 de la superficie de las células T y envía la señal de frenado que el CTLA-4 de superficie no puede enviar porque se destruye antes de llegar. El abatacept no debilita el sistema inmune en general. Reemplaza específicamente el freno que los linfocitos T de Valentina no tienen. El IVIG y el abatacept no son contradictorios. Son dos tratamientos para dos consecuencias distintas del mismo gen roto, en dos tipos de células distintas.”
(Exactly. IVIG replaces the antibodies that Valentina’s B cells cannot make — that addresses the B side problem. Abatacept is exactly the CTLA-4 protein, made as a medication. When abatacept is administered, the CTLA-4 in the medication binds to the same molecules that surface CTLA-4 on T cells would bind and sends the braking signal that surface CTLA-4 cannot send because it is destroyed before it arrives. Abatacept does not weaken the immune system in general. It specifically replaces the brake that Valentina’s T lymphocytes do not have. IVIG and abatacept are not contradictory. They are two treatments for two different consequences of the same broken gene, in two different cell types.)
Carmen was quiet, then: “O sea — no es que tenga sistema débil Y sistema fuerte. Es que el mismo gen roto hace dos cosas malas en dos tipos distintos de células.”
(So — it is not that she has a weak system AND a strong system. It is that the same broken gene does two bad things in two different cell types.)
“Eso es exactamente. El gen LRBA roto produce problemas distintos en distintas células. El IVIG y el abatacept resuelven los dos problemas distintos. No son opuestos — son complementarios.”
(That is exactly it. The broken LRBA gene produces different problems in different cells. IVIG and abatacept solve the two different problems. They are not opposites — they are complementary.)
Valentina started abatacept subcutaneous 125 mg weekly. At eight weeks: diarrhea reduced from eight to ten stools per day to two to three. CRP normalized to 4 mg/L. At sixteen weeks: duodenal biopsy showed improvement from complete villous atrophy to partial atrophy, with reduced intraepithelial lymphocytosis. Weight had returned to baseline. IgG anti-enterocyte antibodies declined to 1:80. She continued IVIG on the same schedule throughout. Ernesto at the sixteen-week visit: “Cuando le diéron el abatacept explicado como el CTLA-4 que Valentina no tiene en la superficie de sus células T — eso hizo que tuviera sentido. No estamos poniendo dos tratamientos contrarios. Estamos poniendo el ingrediente que le falta en cada tipo de célula.” (“When they explained abatacept as the CTLA-4 that Valentina does not have on the surface of her T cells — that made it make sense. We are not giving two opposite treatments. We are giving the missing ingredient in each cell type.”)
Frequently asked questions
How do pediatric immune dysregulation clinic nurses explain to Spanish-speaking parents why IPEX syndrome requires immunosuppression when the disease involves the immune system attacking the body?
The explanation requires establishing that the immune system has two functionally opposite arms — effector lymphocytes that attack targets and regulatory T cells (Tregs) that prevent effector lymphocytes from attacking self-tissues — and that IPEX syndrome is a failure of the regulatory arm alone. FOXP3 encodes the master transcription factor for Tregs. Hemizygous FOXP3 pathogenic variants eliminate Tregs without reducing effector lymphocytes. Without Tregs, effector T cells that completed an immune response continue operating and attack pancreatic beta cells (producing neonatal T1DM), intestinal epithelium (producing secretory enteropathy), and skin (producing severe eczema). Sirolimus suppresses effector T cell proliferation preferentially, because effector T cells depend more on mTOR signaling for metabolic activation than regulatory T cells do. The goal of immunosuppression in IPEX is to suppress the unregulated effector attack on self-tissues — not to reduce immune defense broadly. Infection risk is real and is monitored closely; empirical antibiotics are provided rapidly for fever. The alternative to immunosuppression is continued autoimmune destruction of remaining beta cell mass, intestinal epithelium, and skin by uncontrolled effectors. The curative treatment is hematopoietic stem cell transplantation, which replaces the defective FOXP3-expressing hematopoietic progenitors with functional ones whose T cell progeny can develop Tregs.
How do pediatric immune dysregulation clinic nurses explain to Spanish-speaking parents why ALPS requires ongoing quarterly monitoring when lymph node biopsies have confirmed benign tissue?
The explanation requires distinguishing between two separate consequences of FAS apoptosis failure and establishing that biopsies address one question while surveillance addresses a different one. FAS-mediated apoptosis eliminates both lymphocytes at the end of immune responses (explaining the lymphoproliferation when it fails) and lymphocytes with DNA damage before they can undergo malignant transformation. The pathognomonic ALPS cell — double-negative T cells (DNT, TCRαβ+CD3+CD4−CD8−) — is biologically normal, not transformed, which is why biopsies correctly report benign lymphocytes. The biopsies confirm the current state of the accumulated lymphocytes. Separately, impaired elimination of DNA-damaged lymphocytes creates a prospective elevated cancer risk: ALPS-FAS patients have 10–15× the general-population incidence of Hodgkin and diffuse large B cell lymphoma. In ALPS, lymphoma develops against a background of pre-existing massive lymphoproliferation, making symptom-based detection unreliable. Quarterly biomarker monitoring (vitamin B12, sCD25, DNT cell percentage, LDH) and annual cross-sectional imaging detect markers of malignant transformation in progress — sharply rising LDH, new clonal populations, lymph node architectural transformation — while they are still treatable. Two benign biopsies confirm the biopsied nodes at those moments were benign. They confirm nothing about the longitudinal risk of malignant transformation, which requires longitudinal monitoring.
How do pediatric immune dysregulation clinic nurses explain to Spanish-speaking parents why their daughter with antibody deficiency on IVIG now needs abatacept for autoimmune enteropathy?
The explanation requires establishing that LRBA deficiency produces two mechanistically independent consequences in two different cell types and that IVIG and abatacept address different consequences of the same gene defect. LRBA mediates endosomal vesicle recycling. CTLA-4, the T cell inhibitory molecule that terminates T cell activation by competing with CD28 for B7 ligands on antigen-presenting cells, is constitutively endocytosed from the T cell surface and must be recycled back. LRBA deficiency diverts CTLA-4 to lysosomes for degradation, dramatically reducing surface CTLA-4 expression on T cells. Without surface CTLA-4, T cell activation goes unopposed, producing dysregulated effector T cell activation and autoimmune enteropathy. Simultaneously, LRBA deficiency impairs B cell survival and class switching, producing hypogammaglobulinemia. IVIG replaces the IgG that B cells cannot produce (addressing the B cell consequence). Abatacept is CTLA-4-Ig, a fusion protein that binds B7 ligands with high affinity and delivers the inhibitory co-stimulatory signal that absent surface CTLA-4 cannot provide (addressing the T cell consequence). IVIG and abatacept are not contradictory: they address different cells and different mechanisms of the same LRBA gene defect.
What are the key clinical Spanish phrases for the pediatric immune dysregulation clinic covering IPEX syndrome, ALPS, and LRBA deficiency?
For explaining IPEX syndrome immunosuppression rationale: “El sistema inmune tiene dos partes: los linfocitos efectores que atacan infecciones, y los linfocitos reguladores que frenan a los efectores para que no ataquen el propio cuerpo. La mutación de Emilio en FOXP3 elimina los reguladores — los efectores siguen activos y atacan el páncreas, el intestino y la piel sin freno. El sirolimus reduce los efectores específicamente — es freno para el ataque, no para la defensa contra infecciones.” For explaining ALPS surveillance after benign biopsies: “Las biopsias confirmaron que los linfocitos acumulados ahora mismo son benignos — correcto. La mutación FAS también impide que el cuerpo elimine linfocitos con daño en el ADN, y eso aumenta el riesgo de linfoma diez a quince veces. Los análisis trimestrales buscan ese cambio futuro, no el estado actual que ya confirmaron las biopsias. Son dos preguntas distintas.” For explaining LRBA deficiency and dual treatment rationale: “La mutación de Valentina en LRBA produce dos consecuencias separadas en dos tipos de células: en las células B, falta de anticuerpos — el IVIG reemplaza eso; en los linfocitos T, el freno CTLA-4 no puede reciclarse a la superficie y los linfocitos T atacan el intestino — el abatacept es ese freno en forma de medicamento. Dos tratamientos para dos consecuencias del mismo gen roto.”
What are the most important communication challenges specific to Spanish-speaking families in the pediatric immune dysregulation clinic?
Three structural challenges arise consistently. First, the immunosuppression paradox in Treg deficiency disorders: the family’s model of immune function — immune system = defense system, weakening it = less defense — is accurate and creates a coherent objection to immunosuppression in a disease caused by immune attack on self. The two-arm model (effector vs. regulatory) resolves the apparent paradox by locating the problem in the missing brake rather than in excessive immune activity overall. Second, the benign-biopsy lymphoma-risk disconnect in ALPS: the biopsy is the family’s reference point for cancer presence, and in ALPS, biopsies correctly show benign tissue. The family’s inference — benign biopsies rule out cancer risk — is biologically incomplete. Lymphoma risk in ALPS is prospective and mechanism-based: FAS pathway impairment removes a safeguard against malignant transformation that exists independently of whether current lymphocytes are malignant. Surveillance addresses the prospective transformation risk, not the current benign state. Third, the antibody-deficiency-plus-autoimmunity paradox in LRBA deficiency: the family was given a weak-immune-system diagnosis and built their understanding on that frame. When autoimmunity develops and a medication for autoimmune conditions is proposed, it contradicts the frame without being wrong. The same gene produces different consequences in B cells (antibody deficiency) and T cells (unregulated activation via CTLA-4 surface depletion). IVIG and abatacept address different cell types and different mechanisms — they are complementary, not contradictory. The nurse who explains the mechanism specific to each condition gives the family a model that makes both the diagnosis and the treatment coherent.
Six key Spanish phrases for the pediatric immune dysregulation clinic
- El sistema inmune tiene dos partes: linfocitos efectores que atacan, y linfocitos reguladores que frenan — la mutación FOXP3 elimina solo el freno. — The immune system has two parts: effector lymphocytes that attack, and regulatory lymphocytes that brake — the FOXP3 mutation eliminates only the brake.
- El sirolimus reduce la activación de los efectores que están atacando el páncreas y el intestino — no la capacidad de combatir infecciones. — Sirolimus reduces activation of the effectors attacking the pancreas and intestine — not the capacity to fight infections.
- Las biopsias confirman que los linfocitos acumulados ahora mismo son benignos — los análisis trimestrales detectan si eso cambia hacia algo maligno. — The biopsies confirm the accumulated lymphocytes right now are benign — the quarterly tests detect whether that changes toward something malignant.
- El riesgo de linfoma en el ALPS es diez a quince veces mayor porque la misma mutación impide eliminar linfocitos con daño en el ADN antes de que se transformen. — Lymphoma risk in ALPS is ten to fifteen times higher because the same mutation prevents eliminating lymphocytes with DNA damage before they transform.
- La mutación LRBA produce dos consecuencias: en las células B, faltan anticuerpos; en los linfocitos T, el freno CTLA-4 no llega a la superficie porque se destruye antes de reciclarse. — The LRBA mutation produces two consequences: in B cells, antibodies are missing; in T lymphocytes, the CTLA-4 brake does not reach the surface because it is destroyed before recycling.
- El abatacept es el CTLA-4 en forma de medicamento — hace el frenado que el CTLA-4 de superficie no puede hacer. El IVIG y el abatacept tratan dos problemas distintos del mismo gen roto. — Abatacept is CTLA-4 in medication form — it does the braking that surface CTLA-4 cannot do. IVIG and abatacept treat two different problems from the same broken gene.
For more on related conditions in the pediatric immunology and immune dysregulation setting, see Spanish for pediatric immunodeficiency clinic nurses (covering X-linked agammaglobulinemia, SCID post-transplant live vaccine clearance, and chronic granulomatous disease) and Spanish for pediatric allergy and immunology clinic nurses.